ArticleUrologie (Heidelberg, Germany)2026
[Anticoagulation and platelet aggregation inhibition in urology : Update on peri-interventional management].
Article in Urologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Perioperative management of antithrombotic therapy is challenging in the daily clinical practice and requires an individualized balancing between bleeding and thromboembolic risks. The structured risk stratification is based on patient medical history and validated scores. In cases of low bleeding risk, anticoagulation can often be continued; however, in urology an elevated bleeding risk is frequently present due to the high vascularity of the organs involved. Direct oral anticoagulants (DOAC) are typically only temporarily interrupted and bridging therapy is generally not indicated. The timing of discontinuation is determined by renal function and bleeding risk. Only patients at high thromboembolic risk should receive bridging therapy at full therapeutic dosage. The discontinuation of antiplatelet agents within the first month following stent implantation is associated with a high risk of stent thrombosis.
Indexed as
Identifiers
42734811What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.